Related references
Note: Only part of the references are listed.Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
Jeremy Chataway et al.
LANCET NEUROLOGY (2020)
MAFG-driven astrocytes promote CNS inflammation
Michael A. Wheeler et al.
NATURE (2020)
Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx)
Anthony Feinstein et al.
BMC NEUROLOGY (2020)
Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis
Bjoern Neumann et al.
CELL STEM CELL (2020)
The 2013 clinical course descriptors for multiple sclerosis A clarification
Fred D. Lublin et al.
NEUROLOGY (2020)
Mechanisms underlying progression in multiple sclerosis
Martina Absinta et al.
CURRENT OPINION IN NEUROLOGY (2020)
Serum neurofilament light as a biomarker in progressive multiple sclerosis
Raju Kapoor et al.
NEUROLOGY (2020)
Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis
Wallace J. Brownlee et al.
BRAIN (2019)
Progression of regional grey matter atrophy in multiple sclerosis
Arman Eshaghi et al.
BRAIN (2018)
Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study
Elena H. Martinez-Lapiscina et al.
LANCET NEUROLOGY (2016)